Journal of Clinical Oncology
Articles in this Issue
CONVERGE-01: Dosimetry, randomized dose optimization, dose escalation, and efficacy of ac-225 rosopatamab tetraxetan in participants with PSMA-positive castration-resistant prostate cancer.
TPS289 Background: Prostate specific membrane antigen (PSMA) is a validated target in metastatic castration resistant prostate cancer (CRPC). Use of an al...
Comparison of PSA-based <i>g</i> -rate and conventional PSA metrics in veterans with metastatic prostate cancer (mPC).
188 Background: While PSA is routinely used for monitoring in clinics for pts with mPC, it is not a surrogate endpoint for survival or benefit in the majo...
Frequency and impact of a genome-wide homologous recombination deficiency signature (HRDsig+) on the genomic landscape of clinically advanced penile squamous cell carcinoma (CAPSCC).
824 Background: CAPSCC is a challenging disease with significant need for improvements in effective systemic therapies for patients with surgically incura...
Avelumab in combination with axitinib (Ave + Axi) for first-line (1L) treatment of advanced renal cell carcinoma (aRCC): A systematic literature review (SLR) of real-world effectiveness and safety.
491 Background: Ave + Axi combination is an approved option worldwide for 1L treatment of patients with aRCC based on the results of the JAVELIN Renal 101...
Osteonecrosis of the jaw (ONJ) in patients with metastatic castration resistant prostate cancer (mCRPC) treated with denosumab in a randomized phase III trial comparing 4 vs. 12 weekly administration (REDUSE, SAKK 96/12).
163 Background: While reducing skeletal-related events in patients (pts) with bone metastases (BM), bone protecting agents such as DN have adverse events....
Chimeric RNA landscape in the Chinese population and the role of <i>SFT2D2-TBX19</i> in prostate cancer progression.
406 Background: Specific gene fusions and their fusion products (chimeric transcripts and proteins) have served as ideal diagnostic markers and therapeuti...
Characteristics and clinical outcomes of metastatic testicular cancer in a distinct demographic.
620 Background: Testicular cancer is the most common malignancy among adolescent and young adult (AYA) males (15 – 40 years). While the median age at diag...
Implementing precision oncology in renal cell carcinoma (RCC): Prospective identification of clinical, tissue-based, and circulating factors to refine outcome prediction and support therapeutic choices (SIGNS-RCC TRIAL).
TPS617 Background: At diagnosis, 55% of RCC are localized, and 25% are locally advanced/metastatic (aRCC); an additional 30% develop metastases during fol...
The role of circulating kidney injury molecule-1 (KIM-1) in metastatic renal cell carcinoma (mRCC): A biomarker analysis of Tide-A, a phase 2 study of first-line avelumab (ave) plus intermittent axitinib (axi).
584 Background: KIM-1 was evaluated as plasma circulating biomarker of microscopical residual disease, disease recurrence after nephrectomy, and potential...
Outcomes with multi parametric MRI (mpMRI) compared to diagnostic transurethral resection of bladder tumor (TURBT) in patients (pts) with suspected muscle-invasive bladder cancer (MIBC): A pilot study.
TPS881 Background: TURBT is a standard diagnostic procedure to determine the depth of bladder tumor invasion into the bladder wall, particularly whether t...
Domain-specific large language model for predicting prostate cancer treatment plan.
428 Background: Prostate cancer management presents a significant healthcare burden, with the need to efficiently triage patients for treatment. Our objec...
A phase Ib window of opportunity study of atezolizumab administered intravesically or direct injection in patients undergoing radical cystectomy for bladder cancer: Results of the single dose cohorts.
773 Background: BCG-unresponsive High-risk non-muscle invasive bladder cancer (HRNMIBC) tumours have an ominous prognosis and require effective, tolerable...
Using AI to identify optimal clinical, genomic, and radiographic prognostic features and novel risk classifiers compared to routinely available risk classifiers.
396 Background: This study investigated the use of artificial intelligence (AI) and traditional statistical techniques to identify and validate clinical (...
Updated efficacy, safety, and correlative analysis of a phase II trial in metastatic renal cell carcinoma with coordinated pembrolizumab and high dose IL-2.
554 Background: The CM 214 trial with Nivolumab-ipilimumab recently presented its long term follow up results with regards to efficacy and safety. In this...
Formula-01: A phase Ⅱ study of disitamab vedotin (RC48) intravenous injection combined with BCG intravesical instillation in high-risk non-muscle invasive bladder cancer with HER2 high expression.
TPS894 Background: Intravesical instillation of bacillus Calmette-Guérin (BCG) is the first-choice treatment for intermediate- and high-risk non-muscle in...
Impact of PSMA PET staging on initial treatment in newly diagnosed prostate cancer: An emulated randomized controlled trial.
350 Background: Prostate-specific membrane antigen (PSMA) PET/CT has become a common initial staging modality for localized prostate cancer due to its inc...
PSMA-positive tumor vessels around renal cell carcinoma with high angiogenic potential as therapeutic targets and predictors of tumor recurrence.
561 Background: The expression of prostate-specific membrane antigen (PSMA) protein increases as prostate cancer advances and metastasizes. Recently, 68Ga...
Re-treatment of metastatic castration-resistant prostate cancer patients with radium-223 therapy in daily practice.
183 Background: Radium-223 is a therapeutic option for metastatic castration-resistant prostate cancer (mCRPC) patients with symptomatic bone metastases a...
Quantifying the benefit of salvage radiation versus surveillance for biochemically recurrent prostate cancer after radical prostatectomy.
382 Background: The natural history of biochemical recurrence (BCR) after radical prostatectomy (RP) is heterogeneous, with most patients not progressing...
Safety and efficacy of FGFR inhibitors in urothelial carcinoma: A systematic review and meta-analysis.
782 Background: Urothelial carcinoma is the most frequently occurring bladder cancer and originates from urothelial cells lining the bladder and the urina...
Real-world evidence for factors associated with development of castration-resistant prostate cancer (CRPC).
92 Background: Androgen deprivation therapy (ADT) is foundational for advanced prostate cancer (PCa); luteinizing hormone-releasing hormone (LHRH) agonist...
Avelumab first-line (1L) maintenance therapy in advanced urothelial carcinoma: Final analysis from a real-world study in the UK.
723 Background: In the JAVELIN Bladder 100 phase 3 trial, avelumab 1L maintenance therapy plus best supportive care (BSC) significantly improved overall s...
Grade and volume progression and its association with the Decipher genomic classifier using patients enrolled in a prospective active surveillance protocol.
262 Background: The progression of prostate cancer through serial biopsies in patients on active surveillance is a multifaceted process, with grade and vo...
State of the genitourinary medical oncology workforce in the United States, 2024.
446 Background: There are approximately 13,400 oncologists engaged in patient care in the US as of 2022. As the field of medical oncology becomes subspeci...
Carboplatin in patients with metastatic castration-resistant prostate cancer harboring somatic or germline homologous recombination repair gene mutations: Phase II single-arm trial (CiPHeR).
TPS291 Background: Approximately 20-25% of patients with metastatic castration resistant prostate cancer (mCRPC) harbour a germline or somatic mutation in...